

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



ORGANON

## Betamethasone (0.05%) Ointment Formulation

Version 4.6      Revision Date: 09/30/2023      SDS Number: 1681987-00013      Date of last issue: 04/04/2023  
Date of first issue: 05/18/2017

### SECTION 1. IDENTIFICATION

Product name : Betamethasone (0.05%) Ointment Formulation  
Other means of identification : No data available

#### Manufacturer or supplier's details

Company name of supplier : Organon & Co.  
Address : 30 Hudson Street, 33rd floor  
Jersey City, New Jersey, U.S.A 07302  
Telephone : 1-551-430-6000  
Emergency telephone : 1-215-631-6999  
E-mail address : EHSSTEWARD@organon.com

#### Recommended use of the chemical and restrictions on use


Recommended use : Pharmaceutical  
Restrictions on use : Not applicable

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the Hazardous Products Regulations

Reproductive toxicity : Category 1B  
Specific target organ toxicity - repeated exposure : Category 1 (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland)

#### GHS label elements

Hazard pictograms : 

Signal Word : Danger

Hazard Statements : H360D May damage the unborn child.  
H372 Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through prolonged or repeated exposure.

Precautionary Statements : **Prevention:**  
P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P260 Do not breathe dust, fume, gas, mist, vapors or spray.  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
P280 Wear protective gloves, protective clothing, eye protection and face protection.

#### Response:

P308 + P313 IF exposed or concerned: Get medical attention.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Betamethasone (0.05%) Ointment Formulation

Version 4.6      Revision Date: 09/30/2023      SDS Number: 1681987-00013      Date of last issue: 04/04/2023  
Date of first issue: 05/18/2017

### Storage:

P405 Store locked up.

### Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

### Other hazards

None known.

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

| Chemical name                 | Common Name/Synonym                               | CAS-No.   | Concentration (% w/w)  |
|-------------------------------|---|-----------|------------------------|
| Petrolatum                    | White Vaseline                                    | 8009-03-8 | $\geq 80 - \leq 100$ * |
| Propylene glycol              | 1,2-Propanediol                                   | 57-55-6   | $\geq 10 - < 30$ *     |
| Propylene glycol monostearate | Octadecanoic acid, monoester with 1,2-propanediol | 1323-39-3 | $\geq 1 - < 5$ *       |
| Betamethasone                 | No data available                                 | 378-44-9  | $\geq 0.01 - < 0.1$ *  |

\* Actual concentration or concentration range is withheld as a trade secret

## SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : May damage the unborn child.  
Causes damage to organs through prolonged or repeated exposure.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Betamethasone (0.05%) Ointment Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 04/04/2023  |
| 4.6     | 09/30/2023     | 1681987-00013 | Date of first issue: 05/18/2017 |

Notes to physician : when the potential for exposure exists (see section 8).  
: Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Vapors may form explosive mixtures with air.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Betamethasone (0.05%) Ointment Formulation

Version 4.6      Revision Date: 09/30/2023      SDS Number: 1681987-00013      Date of last issue: 04/04/2023  
Date of first issue: 05/18/2017

- Advice on safe handling : Do not get on skin or clothing.  
Do not breathe dust, fume, gas, mist, vapors or spray.  
Do not swallow.  
Avoid contact with eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.  
Store locked up.  
Keep tightly closed.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives  
Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

| Components                    | CAS-No.   | Value type (Form of exposure)      | Control parameters / Permissible concentration | Basis     |
|-------------------------------|-----------|------------------------------------|--|-----------|
| Petrolatum                    | 8009-03-8 | TWA (Mist)                         | 5 mg/m <sup>3</sup>                            | CA AB OEL |
|                               |           | STEL (Mist)                        | 10 mg/m <sup>3</sup>                           | CA AB OEL |
|                               |           | TWA (Mist)                         | 1 mg/m <sup>3</sup>                            | CA BC OEL |
|                               |           | TWAEV (Mist - Inhalable dust)      | 5 mg/m <sup>3</sup>                            | CA QC OEL |
|                               |           | TWA (Inhalable particulate matter) | 5 mg/m <sup>3</sup>                            | ACGIH     |
| Propylene glycol              | 57-55-6   | TWA (Vapour and aerosols)          | 50 ppm<br>155 mg/m <sup>3</sup>                | CA ON OEL |
|                               |           | TWA (aerosol)                      | 10 mg/m <sup>3</sup>                           | CA ON OEL |
| Propylene glycol monostearate | 1323-39-3 | TWA                                | 10 mg/m <sup>3</sup>                           | CA AB OEL |
|                               |           | TWA (Inhalable)                    | 10 mg/m <sup>3</sup>                           | CA BC OEL |
|                               |           | TWA (Respirable)                   | 3 mg/m <sup>3</sup>                            | CA BC OEL |
|                               |           | TWA (Inhalable)                    | 10 mg/m <sup>3</sup>                           | ACGIH     |

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Betamethasone (0.05%) Ointment Formulation

Version 4.6      Revision Date: 09/30/2023      SDS Number: 1681987-00013      Date of last issue: 04/04/2023  
Date of first issue: 05/18/2017

|               |                           |                                     |                             |          |
|---------------|---------------------------|-------------------------------------|-----------------------------|----------|
|               |                           | particulate matter)                 |                             |          |
|               |                           | TWA (Respirable particulate matter) | 3 mg/m <sup>3</sup>         | ACGIH    |
| Betamethasone | 378-44-9                  | TWA                                 | 1 µg/m <sup>3</sup> (OEB 4) | Internal |
|               | Further information: Skin |                                     |                             |          |
|               |                           | Wipe limit                          | 10 µg/100 cm <sup>2</sup>   | Internal |

**Engineering measures** : Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies.

### Personal protective equipment

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Particulates type

**Hand protection**

**Material** : Chemical-resistant gloves

**Remarks** : Consider double gloving.

**Eye protection** : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**Hygiene measures** : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Betamethasone (0.05%) Ointment Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 04/04/2023  |
| 4.6     | 09/30/2023     | 1681987-00013 | Date of first issue: 05/18/2017 |

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

|  |   |   |
|--|---|---|
| Appearance                                       | : | ointment                                |
| Color  | : | white to off-white                      |
| Odor   | : | No data available                       |
| Odor Threshold                                   | : | No data available                       |
| pH   | : | No data available                       |
| Melting point/freezing point                     | : | No data available                       |
| Initial boiling point and boiling range          | : | No data available                       |
| Flash point                                      | : | > 93.3 °C                               |
| Evaporation rate                                 | : | Not applicable                          |
| Flammability (solid, gas)                        | : | Not classified as a flammability hazard |
| Flammability (liquids)                           | : | Not applicable                          |
| Upper explosion limit / Upper flammability limit | : | No data available                       |
| Lower explosion limit / Lower flammability limit | : | No data available                       |
| Vapor pressure                                   | : | No data available                       |
| Relative vapor density                           | : | Not applicable                          |
| Relative density                                 | : | No data available                       |
| Density  | : | No data available                       |
| Solubility(ies)<br>Water solubility              | : | No data available                       |
| Partition coefficient: n-octanol/water           | : | Not applicable                          |
| Autoignition temperature                         | : | No data available                       |
| Decomposition temperature                        | : | No data available                       |
| Viscosity<br>Viscosity, kinematic                | : | Not applicable                          |
| Explosive properties                             | : | Not explosive                           |

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Betamethasone (0.05%) Ointment Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 04/04/2023  |
| 4.6     | 09/30/2023     | 1681987-00013 | Date of first issue: 05/18/2017 |

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle size : Not applicable

### SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Vapors may form explosive mixture with air.  
Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### **Petrolatum:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Method: OECD Test Guideline 401  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity  
Remarks: Based on data from similar materials

##### **Propylene glycol:**

Acute oral toxicity : LD50 (Rat): 22,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 44.9 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Assessment: The substance or mixture has no acute dermal toxicity

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Betamethasone (0.05%) Ointment Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 04/04/2023  |
| 4.6     | 09/30/2023     | 1681987-00013 | Date of first issue: 05/18/2017 |

---

### Propylene glycol monostearate:

Acute oral toxicity : LD50 (Mouse): > 5,000 mg/kg

### Betamethasone:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
LD50 (Mouse): > 4,500 mg/kg

Acute inhalation toxicity : LC50 (Rat): 0.4 mg/l  
Exposure time: 4 h

### Skin corrosion/irritation

Not classified based on available information.

### Components:

#### Petrolatum:

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation  
Remarks : Based on data from similar materials

#### Propylene glycol:

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

#### Propylene glycol monostearate:

Result : No skin irritation

#### Betamethasone:

Species : Rabbit  
Result : Mild skin irritation

### Serious eye damage/eye irritation

Not classified based on available information.

### Components:

#### Petrolatum:

Species : Rabbit  
Result : No eye irritation  
Method : OECD Test Guideline 405  
Remarks : Based on data from similar materials

#### Propylene glycol:

Species : Rabbit  
Result : No eye irritation  
Method : OECD Test Guideline 405



# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Betamethasone (0.05%) Ointment Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 04/04/2023  |
| 4.6     | 09/30/2023     | 1681987-00013 | Date of first issue: 05/18/2017 |

---

### Betamethasone:

Species : Rabbit  
Result : No eye irritation

### Respiratory or skin sensitization

#### Skin sensitization

Not classified based on available information.

#### Respiratory sensitization

Not classified based on available information.

### Components:

#### Petrolatum:

Test Type : Buehler Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Result : negative  
Remarks : Based on data from similar materials

#### Propylene glycol:

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Result : negative

### Betamethasone:

Routes of exposure : Dermal  
Species : Guinea pig  
Result : Weak sensitizer

### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### Petrolatum:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro  
Result: negative  
Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Method: OECD Test Guideline 474  
Result: negative  
Remarks: Based on data from similar materials

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Betamethasone (0.05%) Ointment Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 04/04/2023  |
| 4.6     | 09/30/2023     | 1681987-00013 | Date of first issue: 05/18/2017 |

---

### Propylene glycol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative

### Betamethasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: positive

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Oral  
Result: equivocal

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

### Carcinogenicity

Not classified based on available information.

### Components:

#### Petrolatum:

Species : Rat  
Application Route : Ingestion  
Exposure time : 2 Years  
Result : negative

#### Propylene glycol:

Species : Rat  
Application Route : Ingestion  
Exposure time : 2 Years  
Result : negative

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Betamethasone (0.05%) Ointment Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 04/04/2023  |
| 4.6     | 09/30/2023     | 1681987-00013 | Date of first issue: 05/18/2017 |

---

### Reproductive toxicity

May damage the unborn child.

### Components:

#### **Petrolatum:**

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Skin contact  
Result: negative  
Remarks: Based on data from similar materials

#### **Propylene glycol:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Mouse  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Mouse  
Application Route: Ingestion  
Result: negative

#### **Betamethasone:**

Effects on fetal development : Species: Rabbit  
Application Route: Intramuscular  
Developmental Toxicity: LOAEL: 0.05 mg/kg body weight  
Result: Fetotoxicity, Malformations were observed.

Species: Rat  
Application Route: Subcutaneous  
Developmental Toxicity: LOAEL: 0.42 mg/kg body weight  
Result: Malformations were observed.

Species: Mouse  
Application Route: Intramuscular  
Developmental Toxicity: LOAEL: 1 mg/kg body weight  
Result: Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

### **STOT-single exposure**

Not classified based on available information.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Betamethasone (0.05%) Ointment Formulation

Version 4.6      Revision Date: 09/30/2023      SDS Number: 1681987-00013      Date of last issue: 04/04/2023  
Date of first issue: 05/18/2017

---

### STOT-repeated exposure

Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through prolonged or repeated exposure.

#### Components:

##### **Betamethasone:**

Target Organs : Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland  
Assessment : Causes damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

#### Components:

##### **Petrolatum:**

Species : Rat  
NOAEL : 5,000 mg/kg  
Application Route : Ingestion  
Exposure time : 2 y

##### **Propylene glycol:**

Species : Rat, male  
NOAEL :  $\geq 1,700$  mg/kg  
Application Route : Ingestion  
Exposure time : 2 y

##### **Betamethasone:**

Species : Rabbit  
LOAEL : 0.05 %  
Application Route : Skin contact  
Exposure time : 10 - 30 d  
Target Organs : Pituitary gland, Immune system, muscle

Species : Rat  
LOAEL : 0.05 %  
Application Route : Skin contact  
Exposure time : 8 Weeks  
Target Organs : thymus gland

Species : Mouse  
LOAEL : 0.1 %  
Application Route : Skin contact  
Exposure time : 8 Weeks  
Target Organs : thymus gland

Species : Dog  
LOAEL : 0.05 mg/kg  
Application Route : Oral  
Exposure time : 28 d  
Target Organs : Blood, thymus gland, Adrenal gland

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Betamethasone (0.05%) Ointment Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 04/04/2023  |
| 4.6     | 09/30/2023     | 1681987-00013 | Date of first issue: 05/18/2017 |

---

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

#### **Betamethasone:**

|              |   |   |
|--------------|---|---|
| Inhalation   | : | Target Organs: Adrenal gland            |
| Skin contact | : | Symptoms: Redness, pruritis, Irritation |

---

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Components:

#### **Petrolatum:**

|                  |   |   |
|------------------|---|---|
| Toxicity to fish | : | LL50 (Pimephales promelas (fathead minnow)): > 100 mg/l<br>Exposure time: 96 h<br>Test substance: Water Accommodated Fraction<br>Method: OECD Test Guideline 203<br>Remarks: Based on data from similar materials |
|------------------|---|---|

|   |   |   |
|---|---|---|
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Daphnia magna (Water flea)): > 10,000 mg/l<br>Exposure time: 48 h<br>Test substance: Water Accommodated Fraction<br>Remarks: Based on data from similar materials |
|---|---|---|

|                                  |   |   |
|----------------------------------|---|---|
| Toxicity to algae/aquatic plants | : | NOEL (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l<br>Exposure time: 72 h<br>Test substance: Water Accommodated Fraction<br>Method: OECD Test Guideline 201<br>Remarks: Based on data from similar materials |
|----------------------------------|---|---|

|  |   |   |
|--|---|---|
| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) | : | NOEC (Daphnia magna (Water flea)): 10 mg/l<br>Exposure time: 21 d<br>Test substance: Water Accommodated Fraction<br>Remarks: Based on data from similar materials |
|--|---|---|

#### **Propylene glycol:**

|                  |   |  |
|------------------|---|--|
| Toxicity to fish | : | LC50 (Oncorhynchus mykiss (rainbow trout)): 40,613 mg/l<br>Exposure time: 96 h |
|------------------|---|--|

|   |   |  |
|---|---|--|
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Ceriodaphnia dubia (water flea)): 18,340 mg/l<br>Exposure time: 48 h |
|---|---|--|

|                                  |   |   |
|----------------------------------|---|---|
| Toxicity to algae/aquatic plants | : | ErC50 (Skeletonema costatum (marine diatom)): 19,300 mg/l<br>Exposure time: 72 h<br>Method: OECD Test Guideline 201 |
|----------------------------------|---|---|

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Betamethasone (0.05%) Ointment Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 04/04/2023  |
| 4.6     | 09/30/2023     | 1681987-00013 | Date of first issue: 05/18/2017 |

---

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Ceriodaphnia dubia (water flea)): 13,020 mg/l  
Exposure time: 7 d

Toxicity to microorganisms : NOEC (Pseudomonas putida): > 20,000 mg/l  
Exposure time: 18 h

### **Betamethasone:**

Toxicity to daphnia and other aquatic invertebrates : EC50 (Americamysis): > 50 mg/l  
Exposure time: 96 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 34 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 34 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.052 mg/l  
Exposure time: 32 d  
Method: OECD Test Guideline 210

NOEC (Oryzias latipes (Japanese medaka)): 0.07 µg/l  
Exposure time: 219 d  
Method: OECD Test Guideline 229

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 8 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

### **Persistence and degradability**

#### **Components:**

##### **Petrolatum:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 31 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301F  
Remarks: Based on data from similar materials

##### **Propylene glycol:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 98.3 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301F

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Betamethasone (0.05%) Ointment Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 04/04/2023  |
| 4.6     | 09/30/2023     | 1681987-00013 | Date of first issue: 05/18/2017 |

### Bioaccumulative potential

#### Components:

##### Propylene glycol:

Partition coefficient: n-octanol/water : log Pow: -1.07  
Method: Regulation (EC) No. 440/2008, Annex, A.8

##### Betamethasone:

Partition coefficient: n-octanol/water : log Pow: 2.11

##### Mobility in soil

No data available

##### Other adverse effects

No data available

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

## SECTION 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,  
N.O.S.  
(betamethasone)

Class : 9  
Packing group : III  
Labels : 9  
Environmentally hazardous : yes

#### IATA-DGR

UN/ID No. : UN 3077  
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.  
(Betamethasone)

Class : 9  
Packing group : III  
Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 956  
Packing instruction (passenger aircraft) : 956  
Environmentally hazardous : yes

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Betamethasone (0.05%) Ointment Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 04/04/2023  |
| 4.6     | 09/30/2023     | 1681987-00013 | Date of first issue: 05/18/2017 |

---

### IMDG-Code

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Betamethasone)  
Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### Domestic regulation

#### TDG

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Betamethasone)  
Class : 9  
Packing group : III  
Labels : 9  
ERG Code : 171  
Marine pollutant : yes(Betamethasone)

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

---

## SECTION 15. REGULATORY INFORMATION

### The ingredients of this product are reported in the following inventories:

AICS : not determined  
DSL : not determined  
IECSC : not determined

---

## SECTION 16. OTHER INFORMATION

### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
CA AB OEL : Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)  
CA BC OEL : Canada. British Columbia OEL  
CA ON OEL : Ontario Table of Occupational Exposure Limits made under the Occupational Health and Safety Act.



# SAFETY DATA SHEET

according to the Hazardous Products Regulations



ORGANON

## Betamethasone (0.05%) Ointment Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 04/04/2023  |
| 4.6     | 09/30/2023     | 1681987-00013 | Date of first issue: 05/18/2017 |

|                   |   |   |
|-------------------|---|---|
| CA QC OEL         | : | Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants |
| ACGIH / TWA       | : | 8-hour, time-weighted average   |
| CA AB OEL / TWA   | : | 8-hour Occupational exposure limit  |
| CA AB OEL / STEL  | : | 15-minute occupational exposure limit   |
| CA BC OEL / TWA   | : | 8-hour time weighted average  |
| CA ON OEL / TWA   | : | Time-Weighted Average Limit (TWA)   |
| CA QC OEL / TWAEV | : | Time-weighted average exposure value  |

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

|  |   |   |
|--|---|---|
| Sources of key data used to compile the Material Safety Data Sheet | : | Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <a href="http://echa.europa.eu/">http://echa.europa.eu/</a> |
|--|---|---|

|               |   |            |
|---------------|---|------------|
| Revision Date | : | 09/30/2023 |
| Date format   | : | mm/dd/yyyy |

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Betamethasone (0.05%) Ointment Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 04/04/2023  |
| 4.6     | 09/30/2023     | 1681987-00013 | Date of first issue: 05/18/2017 |

---

relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8